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Background: Despite the well recognized protective effect of cruciferous vegetables against 
various cancers, including human colorectal cancers, little is known about how this effect is 
conferred. It is thought that some phytochemicals found only in these vegetables confer the 
protection. These compounds include the glucosinolates, of which indole-3-carbinol is one. They 
are known to induce carcinogen-metabolizing (phase II) enzymes, including the glutathione 
S-transferase (GST) family. Other effects in humans are not well documented. We wished to 
assess the effect of indole-3-carbinol on GST enzymes.
Methods: We carried out a placebo-controlled human volunteer study. All patients were given 
400 mg daily of indole-3-carbinol for three months, followed by placebo. Serum samples were 
tested for the GSTM1 genotype by polymerase chain reaction. Serum GST levels were assessed 
using enzyme-linked immunosorbent assay and Western Blot methodologies.
Results: Forty-nine volunteers completed the study. GSTM1 genotypes were obtained for 
all but two volunteers. A slightly greater proportion of volunteers were GSTM1-positive, 
in keeping with the general population. GST was detected in all patients. Total GST level 
was not affected by indole-3-carbinol dosing compared with placebo. Although not statisti-
cally significant, the GSTM1 genotype affected the serum GST level response to indole-
3-carbinol.
Conclusion: Indole-3-carbinol does not alter total serum GST levels during prolonged 
  dosing.
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Introduction
There is strong evidence that diets including a large vegetable component confer 
protection against various human cancers including colorectal cancer.1–6 The underly-
ing mechanism(s) for this protective effect is poorly understood. Vegetables of the 
brassica genus are known to provide significant protection. Compounds from these 
vegetables, including the glucosinolates and their metabolites, have been shown 
in in vitro studies to inhibit the proliferation of and induce apoptosis in various 
human cancer cell lines, act as strong antioxidants, and induce the production of 
both phase I and phase II carcinogen-metabolizing enzymes.7 The glucosinolates are 
found in several plant groups, but the only human dietary source is from cruciferous 
vegetables.8–10 We wished to quantify the effect of one of these compounds, indole-
3-carbinol, on human serum glutathione transferase levels as a logical progres-
sion of our in vitro work,11,12 in a manner similar to that suggested by Kristal and 
Lippman.13Therapeutics and Clinical Risk Management 2010:6 226
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Materials and methods
Volunteers
Fifty-six volunteers consented to take part in the double-blind 
pilot study. They were recruited from advertisements in the 
local press, from family members of patients attending the 
Hunter Family Cancer Service, and as a result of media 
interest in our laboratory studies. Because this was a pilot 
study, no sample size or power calculation was made. Ethics 
approval was obtained from the Hunter Area Research Ethics 
Committee.
Dosing and blood collection
A dose of 400 mg of indole-3-carbinol was to be taken 
each day based on our previous laboratory work and other 
  studies.14 At the initial visit, volunteers provided a baseline 
blood sample and were provided with sufficient tablets until 
the following meeting. Venous blood was obtained in the 
usual manner, mostly from the antecubital fossa, using the 
Vacuette® system (Greiner Bio-One, Interpath, West Heidel-
berg, Australia). Blood suitable for genotyping was retrieved 
in standard specimen bottles containing ethylenediamine 
tetra-acetic acid. A total of 50 mL of blood was obtained. 
A further five meetings occurred, during which additional 
blood samples were taken and further tablets provided. 
After the third visit, volunteers changed from indole-3-
carbinol to placebo tablets for the following three months. 
No tablets were given at the final appointment. Volunteers 
were advised to continue their normal diet throughout the 
study period.
Genotyping for glutathione  
transferase Mu
Whole blood was stored at −20°C and the genotype assessed 
using the polymerase chain reaction (PCR). The following 
primers were utilized (Life Technologies, Melbourne, 
  Australia):
•  GSTM1.16com    GCTTCACGTGTTATGAAGGTTC
•  GSTM1.E7B  TTGGGAAGGCGTCCAAGCAG
•  BGLOBIN.FOR    CAACTTCATCCACGTTCACC
•  BGLOBIN.REV  GAAGAGCCAAGGACAGTTAC
DNA was extracted from a whole blood sample using 
reagents specified for the BioRobot M48 (Qiagen, Doncaster, 
Australia). This was then mixed with 30.55 µL of H2O, 4 µL 
dNTPs (2.5 mM) 200 mM (Promega, Annandale, Australia), 
5 µL buffer (10×) (Promega), 1.25 µL of primers, 0.2 µL 
Taq (5 U/mL) (Promega) up to a total volume of 50 µL. 
An automated PCR was carried out using the Eppendorf 
Mastercycler (EpGradient S, Sydney, Australia). Initially 
the samples were denatured for five minutes at 94°C, with a 
further 14 cycles, each cycle comprising 30 seconds at 94°C, 
45 seconds at 60–54.5°C (step-down 0.5°C/two cycles), and 
one minute at 72°C. This was then followed by 30 cycles, 
each cycle consisting of 94°C for 30 seconds, 53.5°C for 
45 seconds, and 72°C for 60 seconds. Once the cycling reac-
tion was complete, a final extension period of 10 minutes at 
72°C was performed. The resulting 132bp GSTM1 samples 
were digested with Hae11 enzyme (10 U/mL) at 37.5°C for 
3.5 hours. This revealed the homozygous, heterozygous, or 
null genotype (alleles) of GSTM1. The polymorphism was 
evaluated by gel electrophoresis (2% agarose), and the DNA 
levels were checked using a spectrophotometer.
Phenotyping of glutathione  
transferase Mu
Serum was initially separated from the whole blood and 
stored at −20°C. The degree of glutathione S-transferase 
(GST) expression was assessed using both an enzyme-
linked immunosorbent assay (ELISA) and Western Blot 
technique.
ELISA methodology
The wells of 96-well Polysorb ELISA plates (NUNC, Sydney, 
Australia) were coated with 10 µL of serum from volunteers. 
These were then incubated at 37°C for 2–3 hours. The plates 
were then washed and incubated following administration of 
blocking buffer (10% skim milk, 1% Tween 20) for a further 
60 minutes at 37°C. The primary antibody (rabbit anti-human 
GST, donated by Professor Clancy, University of Newcastle, 
Australia) was added and incubated for another 120 minutes 
at 37°C. The plates were washed again and more blocking 
buffer applied prior to further incubation for 60 minutes at 
37°C. Following this, the secondary antibody (anti-rabbit 
IgG-HRP conjugated, donated by Professor Clancy, Univer-
sity of Newcastle, Australia) was applied and reincubated at 
37°C for two hours. The plates were then read in a microplate 
reader at 405 nm after the horseradish peroxidase (HRP) 
substrate (ABST) was fixed. A control plate of pure GST was 
run in a similar fashion for reasons of comparison.
Western Blot methodology
The serum samples were subjected to polyacrylamide gel 
(12.5%) electrophoresis. The gel was run at 110 V for 
75 minutes. Following this, the gel was placed over a sheet Therapeutics and Clinical Risk Management 2010:6 227
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of nitrocellulose and the protein in the gel was transferred 
to the nitrocellulose electrophorectically in transfer buffer 
(1× Tris, glycine plus 20% methyl alcohol). Blocking buffer 
was then prepared by adding 0.2% Tween 20 and 10% skim 
milk powder to a solution of 10 mM Tris and 100 mM NaCl. 
The nitrocellulose was then placed in this buffer solution for 
120 minutes with shaking. The blocking buffer was removed 
and a 1/10000 dilution of the first antibody was prepared 
and added to the membrane. The reaction was incubated 
for 90 minutes at room temperature and removed. A further 
application of blocking buffer was applied for 90 minutes. 
The nitrocellulose was then placed in the secondary anti-
body (1/5000 or 1/10000 in blocking buffer) and incubated 
for another 90 minutes at room temperature (shaking). Two 
  milliliters of ECL developing reagent (Amersham Biosci-
ences, Rydalmere, Australia) was prepared and spread onto 
two glass slides, according to the manufacturer’s instructions. 
The resultant membrane was exposed to Hyperfilm ECL 
(Amersham Biosciences) for five to 10 minutes, followed 
by developing and visualization. This was done primarily to 
validate the results of the ELISA tests.
Statistics
The outcome measure of serum glutathione transferase level 
was measured for both treatment and placebo. These mea-
sures were analysed as continuous variables and the effect of 
the predictor variables (ie, age, sex, diet) on the mean value 
for the outcome variables was determined with regression 
or analysis of variance (ANOVA), (unpaired t-test if the 
predictor had only two levels). To determine the effect of 
indole-3-carbinol, the difference between the treatment and 
placebo groups was analyzed to determine the impact on the 
mean change. The null hypothesis of no change was assumed, 
and statistical significance was taken as P  0.05.
Results
Of the 56 volunteers who consented to take part in the study, 
seven withdrew. The reasons given were inconvenience (n = 
3), a newly diagnosed medical condition (1), tiredness (1, 
whilst on the trial preparation), and diarrhea (2, whilst on 
the trial preparation). The GSTM1 genotype could not be 
determined in two volunteers, who were excluded from 
further analysis. Glutathione transferase was detectable in 
all the remaining volunteers (Figure 2).
Demographics of volunteers
The median age of volunteers who completed the trial was 
58 years (range 20–79). Slightly more females took part 
(57.1% versus 42.9%) and the majority were “never” smokers 
(never, 55.1%; no longer, 38.8%; current, 6.1%).
Results of genotyping
Of the 49 volunteers who completed the trial in the two 
phases, a GSTM1 genotype was obtainable for all but two 
volunteers (one male and one female). Of the remaining 
47 volunteers who completed the study, 25 (53.2%) were 
positive for GSTM1, which is comparable with the normal 
population in other studies.15–20 Of these, six were 1a/1a or 1a/
null-positive and the remainder were 1b/1b or 1b/null. There 
was no significant difference between GSTM1 genotype for 
volunteers by age (GSTM1-null: 50 years, 60.0% versus 
50 years, 40.6%; P = 0.21) nor by gender (GSTM1-null: 
male, 45.0% versus female 48.1%; P = 0.82).
Effects of indole-3-carbinol  
on serum GST
When all results were considered, there was no significant 
difference in mean serum GST levels for volunteers receiv-
ing indole-3-carbinol or placebo (indole-3-carbinol, 0.168; 
  placebo, 0.168; P = 0.84; Figure 1).
The results were then analyzed as matched pairs; that 
is, the difference in the mean serum GST level at times 1 
and 2 for indole-3-carbinol against the mean serum GST 
level at times 1 and 2 for placebo. There was no statisti-
cally significant mean difference (indole-3-carbinol, 0.173; 
  placebo, 0.170; difference, 0.003; P = 0.67).
We then considered the matched pairs for all the serum 
GST levels on indole-3-carbinol against the baseline serum 
GST levels and the matched time equivalent on placebo. 
In general, indole-3-carbinol did not affect serum GST levels 
(Table 1); however, there was nonstatistically significant 
increase in serum GST level following the three months of 
treatment with indole-3-carbinol against the baseline.
Effect of indole-3-carbinol on serum  
GST by GSTM1 genotype
We also compared the effect of indole-3-carbinol on serum 
GST levels according to GSTM1 genotype. Although not 
statistically significant, indole-3-carbinol caused a decrease 
in GST levels in GSTM1-null volunteers and an increase 
in GST levels in GSTM1-positive volunteers (P = 0.48; 
Table 2).
Discussion
We have successfully completed a double-blind, placebo-
controlled, pilot study using indole-3-carbinol, without undue Therapeutics and Clinical Risk Management 2010:6 228
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or intolerable adverse events. In this study, indole-3-carbinol 
had no effect on serum glutathione transferase levels 
when compared with placebo. Using the matched-pairs 
analysis again there was no difference in serum glutathione 
  transferase levels. Against the baseline serum glutathione 
transferase levels, however, treatment with indole-3-carbinol 
did increase serum glutathione transferase levels, although 
not to a level of statistical significance. Such differences were 
not seen when treatment was compared with the equivalent 
placebo period. These differences between treatment and 
placebo periods and treatment and baseline periods are 
not easily explained, but they may be accounted for by the 
distribution and function of glutathione transferase and its 
isoenzymes.
Cytosolic glutathione transferases “mop up” the byprod-
ucts of normal oxidative stress, such as lipid peroxidation 
as well as xenobiotics.21–24 The enzymes do this primarily 
by attaching a glutathione molecule to electrophiles, mak-
ing them water-soluble, which facilitates urinary or biliary 
excretion.19,25–27 This is the first step in the formation of 
mercapturic acids, a pathway which results in the elimina-
tion of potentially toxic compounds from the body.19,28–30 
Within mammalian cells, at least five different isoenzymes 
of glutathione transferases have been discovered. The most 
widely studied to date have been named as follows: GSTα, 
GSTµ, GSTπ, GSTθ and GSTγ.20,22 They all have differ-
ent substrate specificity, but there is significant crossover 
of function.22,28,31 The regulation of cytosolic glutathione 
transferases is subject to a complex set of endogenous and 
exogenous parameters including developmental-, gender-, 
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Figure 1 Mean serum GST levels for I3C (I) and placebo (P) – [Units – µg/ml].
Table 1 Results of matched pairs t-tests for all samples
Paired test Mean difference Standard error Probability
I3C 1 - Blood 0 0.01037 0.00910 0.26
I3C 2 - Blood 0 0.01393 0.00788 0.08
I3C End - Blood 0 0.00192 0.00978 0.85
I3C 1 - P 1 0.01083 0.01088 0.33
I3C 1 - P 2 0.00145 0.01039 0.89
I3C 2 - P 1 0.00926 0.00930 0.33
I3C 2 - P 2 0.00110 0.00964 0.91
Abbreviations: Blood 0, baseline; I3C 1, indole-3-carbinol after first treatment period; 
I3C 2, indole-3-carbinol after second treatment period; I3C End, indole-3-carbinol end 
of treatment period; P 1 after first placebo period; P 2 after second placebo period.
Table 2 The effect of indole-3-carbinol on serum GST levels by 
GSTM1 genotype
Variable 
 
Least 
squares 
mean
Standard 
error 
Difference 
 
Probability 
 
GST null + 
placebo
0.1835 0.0116  
−0.0032
GST null +  
indole-3- 
carbinol
0.1803 0.0113
0.48
GST positive + 
placebo
0.1582 0.0108  
0.0089
GST positive + 
indole-3- 
carbinol
0.1671 
 
0.0108 
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and tissue-specific factors, as well as a large number of 
xenobiotic agents, such as polycyclic aromatic hydrocar-
bons, reactive oxygen species, isothiocyanates, and drugs.31 
The genetic and sporadic loss of glutathione transferase 
isoenzymes is known to cause upregulation of the remain-
ing transferases.22 Persons deficient in certain isoenzymes 
are thought to be more susceptible to cancers of the lung, 
bladder, prostate, colon, and rectum.17,20,32–35
The vast majority of glutathione transferases in the human 
body are found in the liver and small intestine. GSTµ is less 
organ-specific than the other glutathione transferases.19 It is 
found in relatively low levels in lung and colon tissue 36,37 
and in high levels in the liver.36
The mechanism and site of action for the chemoprotective 
effects of cruciferous vegetables is not known. It has been 
postulated that the effects are localized within the gut lumen. 
This may be as a result of direct inhibition of proliferation/
induction of apoptosis in abnormal/cancer cells or the induc-
tion of local carcinogen-metabolizing enzymes. This does 
not explain the regression of carcinoma in situ of the cervix 
when indole-3-carbinol is administered orally.14
The evidence for an increase in overall GST activity and 
that within specific tissues is equivocal. Studies in rats fed 
brussels sprout extract or cabbage-substituted diets showed 
an overall increase in GST activity.38,39 In human studies, no 
effect on overall GST activity was noted in subjects fed test 
diets of brussels sprouts40,41 or broccoli pills.25 Other stud-
ies of rats which were fed brussels sprouts have shown an 
increase in the glutathione transferase activity of intestinal 
cells.42
Several studies have looked at cancer risk in GSTM1-null 
patients in relation to brassica consumption. These studies 
would suggest that a greater intake of brassica vegetables 
or extracts could confer greater protection in GSTM1-null 
patients. These results have been explained by the slower 
metabolism of the isothiocyanates in the absence of the 
GSTµ, prolonging their chemoprotective effect.
In our study, indole-3-carbinol was found to cause an 
increase in serum glutathione transferase levels in those 
who were GSTM1-positive and, conversely, a decrease 
in those who were GSTM1-null. One might expect such a 
pattern because GSTµ expression cannot be induced in null 
individuals. This may also indicate that indole-3-carbinol 
induces GSTµ specifically and has an inhibitory or no effect 
on the other isoenzymes, despite the observed compensa-
tory mechanism described above. It may be that isoenzyme 
activity in specific tissues is induced following administra-
tion of brassica vegetables, unrefined extracts, or specific 
glucosinolate metabolites. This induction may be at a level 
not detectable when overall glutathione transferase activ-
ity is considered.43 Glutathione transferases are abundant 
in the liver and much less so in other tissues,44 such that 
induction of already saturated cells is futile. In extrahepatic 
tissues, however, a modest induction in specific glutathione 
transferase isoenzymes is achievable,31,41,43,45 and may be of 
biologic significance.
GSTM1-positive volunteers with a 1a/1a or 1a/null allele 
status had higher serum levels of GST (not significant, data 
not shown) than the rest. It may be that the 1a genotype gives 
rise to greater expression of the GSTµ isoenzyme, increasing 
overall GST levels, or 1a may in fact be relatively inactive 
so there is greater compensatory expression of the other 
isoenzymes. Different phenotypes have been found between 
homozygous and heterozygous GSTM1-positive individuals. 
In a study by Moore et al, individuals who were GSTM1+/+ 
were found to be at greater risk of developing colorectal 
adenomas than either GSTM1+/− or −/− individuals.46 Some 
authors have suggested that these phenotypic differences 
may account for the lack of evidence for any increased cancer 
risk attributable to glutathione transferase deficiency, as most 
studies do not differentiate homozygous from heterozygous 
positive individuals.22
These results raise many questions. The relatively small 
sample size may have reduced the statistical power of some 
of the observations, and a larger trial looking particularly at 
specific isoenzymes should answer some of these. The dif-
ferences observed for indole-3-carbinol against the baseline 
tests implies that indole-3-carbinol has some effect in the 
manner to be expected from the previous work by ourselves 
and others. The lack of any difference against placebo might 
56 volunteers 
consented 
49 volunteers 
completed study 
47 volunteers 
in analysis
7 withdrawals 
2 not genotyped 
Figure 2 Flow diagram of volunteer selection process.Therapeutics and Clinical Risk Management 2010:6 230
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suggest that the placebo tablets, which only contained rice 
flour, may themselves have had some effects on the systems 
we were investigating. Measurement of individual GST 
isoenzymes was not available in this study. We intended to 
measure GST Mu levels using the formerly available MuKit 
(Biotrin, Ireland). However, this was not available in sufficient 
quantities to enable testing of all samples. More enzyme- or 
tissue-specific testing may provide very different results from 
those we found.
The results also question the perceived role that 
  indole-3-carbinol plays in chemoprevention. It may be that 
indole-3-carbinol is very specific in terms of which gluta-
thione transferase is induced whereas other components of 
brassica vegetables, for example, sulforaphane, may have a 
more global influence on phase II enzymes. Indole-3-carbinol 
and other isothiocyanates are known to act on cancer cells by 
mechanisms other than induction of carcinogen-metabolizing 
enzyme systems.47 We plan to carry out a further trial using 
sulforaphane, and do additional work using human serum 
and cancer cell lines.
Conclusion
We have conducted a study of indole-3-carbinol in humans 
with no deleterious or significant side effects. We found 
glutathione transferase to be present in all volunteers even 
those who were GSTM1-negative. Dosing with indole-3-
carbinol did not appear to alter serum levels of glutathione 
transferase. This can be explained by several mechanisms. 
Indole-3-carbinol is very specific and it does globally induce 
the production of glutathione transferase, but only one of 
its isoenzymes. Small increases in isoenzymes may not be 
detectable when global glutathione transferase levels are 
being measured in the serum. This may indicate that indole-
3-carbinol has a role to play in the treatment of colorectal 
cancer, either in those who are at increased risk or follow-
ing diagnosis. Whilst some aspects of indole-3-carbinol 
metabolism have been described,48 much of its metabolism 
and actions remain undiscovered.
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